Baird Raises Price Target on Innoviva (INVA) as GSK Announces Strong Sales
Tweet Send to a Friend
Baird reiterated a Neutral rating on Innoviva (NASDAQ: INVA), and raised the price target to $11.00 (from $9.00), after GSK ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
